Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$23.53 -3.1%	$23.85	$14.75 ▼ $26.58	$2.87B	0.72	1.13 million shs	1.11 million shs
CPSR Capstar Special Purpose Acquisition	$24.09 -0.1%	$8.28	$6.06 ▼ $12.23	$831.27M	0.07	556,189 shs	3 shs
CRNX Crinetics Pharmaceuticals	$31.77 -1.2%	$31.12	$24.10 ▼ $62.53	$2.97B	0.28	846,245 shs	557,240 shs
VKTX Viking Therapeutics	$26.08 -8.7%	$26.46	$18.92 ▼ $81.73	$2.93B	0.65	4.07 million shs	6.08 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	-3.13%	-9.05%	+0.56%	+11.94%	+52.30%
CPSR Capstar Special Purpose Acquisition	-0.01%	+0.32%	+0.78%	+2.21%	+269.25%
CRNX Crinetics Pharmaceuticals	-1.24%	-3.76%	+1.53%	-7.83%	-33.51%
VKTX Viking Therapeutics	-8.75%	-6.29%	-1.84%	-15.57%	-50.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.7672 of 5 stars	3.6	2.0	0.0	3.9	3.2	3.3	2.5
CPSR Capstar Special Purpose Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	3.5228 of 5 stars	3.5	0.0	0.0	3.7	2.8	2.5	0.0
VKTX Viking Therapeutics	4.397 of 5 stars	4.5	1.0	0.0	4.7	2.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.25	Buy	$32.83	39.54% Upside
CPSR Capstar Special Purpose Acquisition	0.00	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	2.91	Moderate Buy	$74.56	134.67% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	234.18% Upside

Current Analyst Ratings Breakdown

Latest CPSR, VKTX, CPRX, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/24/2025	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00
4/24/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
4/17/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
4/8/2025	VKTX Viking Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$30.00
3/26/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
3/25/2025	CRNX Crinetics Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$534.65M	5.37	$2.19 per share	10.72	$3.30 per share	7.13
CPSR Capstar Special Purpose Acquisition	N/A	N/A	N/A	N/A	($1.18) per share	N/A
CRNX Crinetics Pharmaceuticals	$760K	3,913.94	N/A	N/A	$8.07 per share	3.94
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$71.41M	$1.57	19.94	11.05	3.31	31.01%	40.79%	34.87%	8/6/2025 (Estimated)
CPSR Capstar Special Purpose Acquisition	-$15.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	-$214.53M	-$3.82	N/A	N/A	N/A	N/A	-36.12%	-31.89%	8/6/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-11.93%	-11.57%	7/23/2025 (Estimated)

Latest CPSR, VKTX, CPRX, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CPSR Capstar Special Purpose Acquisition	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	5.11	4.92
CPSR Capstar Special Purpose Acquisition	N/A	0.13	0.13
CRNX Crinetics Pharmaceuticals	N/A	16.39	16.38
VKTX Viking Therapeutics	N/A	36.47	36.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
CPSR Capstar Special Purpose Acquisition	64.87%
CRNX Crinetics Pharmaceuticals	98.51%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
CPSR Capstar Special Purpose Acquisition	N/A
CRNX Crinetics Pharmaceuticals	4.60%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	121.98 million	106.15 million	Optionable
CPSR Capstar Special Purpose Acquisition	2	34.50 million	N/A	Not Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	87.17 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	106.20 million	Optionable

CPSR, VKTX, CPRX, and CRNX Headlines

Recent News About These Companies

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.7% - Should You Sell?

June 13 at 1:55 PM | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Holdings Lifted by Compagnie Lombard Odier SCmA

June 13 at 5:54 AM | marketbeat.com

Viking Therapeutics (VKTX) Rises on Expected Developments

June 12 at 8:30 PM | insidermonkey.com

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

June 12 at 6:46 PM | zacks.com

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

June 12 at 8:46 AM | finance.yahoo.com

Harbor Capital Advisors Inc. Sells 14,094 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 12 at 4:51 AM | marketbeat.com

Viking Therapeutics Target of Unusually High Options Trading (NASDAQ:VKTX)

June 12 at 2:42 AM | americanbankingnews.com

Brokers Issue Forecasts for VKTX FY2026 Earnings

June 12 at 1:45 AM | americanbankingnews.com

Analysts Issue Forecasts for VKTX FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Wesbanco Bank Inc. Purchases 12,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 11 at 4:58 AM | marketbeat.com

Viking Therapeutics Target of Unusually Large Options Trading (NASDAQ:VKTX)

June 10, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Up 7.1% - Still a Buy?

June 10, 2025 | marketbeat.com

Was Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)?

June 9, 2025 | msn.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives $87.15 Average Price Target from Brokerages

June 9, 2025 | americanbankingnews.com

1 Stock Down 34% This Year to Buy and Hold

June 8, 2025 | fool.com

39,652 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Bought by RFG Advisory LLC

June 6, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by Analysts

June 6, 2025 | marketbeat.com

Profit Investment Management LLC Buys 44,055 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 2, 2025 | marketbeat.com

Deutsche Bank AG Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 2, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires New Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 31, 2025 | marketbeat.com

PKO Investment Management Joint Stock Co Purchases Shares of 15,000 Viking Therapeutics, Inc. (NASDAQ:VKTX)

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPSR, VKTX, CPRX, and CRNX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$23.53 -0.76 (-3.13%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$23.80 +0.27 (+1.15%)

As of 06/13/2025 07:44 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Capstar Special Purpose Acquisition NYSE:CPSR

Capstar Special Purpose Acquisition Corp. is a blank check company. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the consumer, healthcare, and technology, media and telecommunications industries. The company was incorporated in 2020 and is based Austin, Texas.

Crinetics Pharmaceuticals NASDAQ:CRNX

$31.77 -0.40 (-1.24%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$31.76 0.00 (-0.02%)

As of 06/13/2025 04:44 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Viking Therapeutics NASDAQ:VKTX

$26.08 -2.50 (-8.75%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$26.22 +0.14 (+0.54%)

As of 06/13/2025 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time